A5013572664- Asthma and respiratory diseases
- SARS-CoV-2 and COVID-19 Research
- COVID-19 Clinical Research Studies
- Antimicrobial Resistance in Staphylococcus
- Cosmology and Gravitation Theories
- Evolution and Genetic Dynamics
- Respiratory and Cough-Related Research
- Inhalation and Respiratory Drug Delivery
- Antibiotics Pharmacokinetics and Efficacy
- Clostridium difficile and Clostridium perfringens research
- Black Holes and Theoretical Physics
- Multiple Sclerosis Research Studies
- Galaxies: Formation, Evolution, Phenomena
- Mathematical and Theoretical Epidemiology and Ecology Models
- Infection Control in Healthcare
- Long-Term Effects of COVID-19
- Eosinophilic Esophagitis
- Peripheral Neuropathies and Disorders
- Antibiotic Use and Resistance
- Monoclonal and Polyclonal Antibodies Research
- Nosocomial Infections in ICU
- Computational Drug Discovery Methods
- Rheumatoid Arthritis Research and Therapies
- Pulsars and Gravitational Waves Research
- HIV Research and Treatment
System Simulation (United Kingdom)
2024
GlaxoSmithKline (United Kingdom)
2012-2023
GlaxoSmithKline (Sri Lanka)
2022
GlaxoSmithKline (United States)
2020-2022
GlaxoSmithKline (Netherlands)
2022
Age UK
2021
Glaxosmithkline (Finland)
2020
University of Florida
2020
Columbus Oncology and Hematology Associates
2020
McGill University
2018
The threat to human health posed by antibiotic resistance is of growing concern. Many commensal and pathogenic organisms have developed well established newer antibiotics. major selection pressure driving changes in the frequency volume drug use. However, establishing a quantitative relationship between use has proved difficult. Using population genetic methods epidemiological observations, we report an analysis influence selective imposed on temporal resistance. Analytical expressions are...
Older patients and those with comorbidities who are infected SARS-CoV-2 may be at increased risk of hospitalization death. Sotrovimab is a neutralizing antibody for the treatment high-risk to prevent COVID-19 progression.To evaluate efficacy adverse events sotrovimab in preventing progression mild moderate severe disease.Randomized clinical trial including 1057 nonhospitalized symptomatic, least 1 factor conducted 57 sites Brazil, Canada, Peru, Spain, US from August 27, 2020, through March...
<h3>Objective</h3> To assess dose-response effects of the anti-CD20 monoclonal antibody ofatumumab on efficacy and safety outcomes in a phase 2b double-blind study relapsing forms multiple sclerosis (RMS). <h3>Methods</h3> Patients (n = 232) were randomized to 3, 30, or 60 mg every 12 weeks, 4 placebo for 24-week treatment period, with primary endpoint cumulative number new gadolinium-enhancing lesions (per brain MRI) at week 12. Relapses safety/tolerability assessed, CD19+ peripheral blood...
Vancomycin-resistant enterococci (VRE) recently have emerged as a nosocomial pathogen especially in intensive-care units (ICUs) worldwide. Transmission via the hands of health-care workers is an important determinant spread and persistence VRE-endemic ICU. We describe transmission pathogens by using micro-epidemiological framework based on dynamics vector-borne diseases. By concept basic reproductive number, R 0 , defined average number secondary cases generated one primary case, we show...
Little is known about the amount of cross-transmission, risk factors for infection, and relative effectiveness infection control procedures when methicillin-resistant Staphylococcus aureus (MRSA) occurs at highly endemic levels in intensive care units. A cohort study was done to identify exposures associated with cases that likely were result cross-transmission (i.e., occurring clusters indistinguishable MRSA macrorestriction profiles). Fitting a simple stochastic model ascertained data...
The emergence of antibiotic resistance in a wide variety important pathogens humans presents worldwide threat to public health. This paper describes recent work on the use mathematical models and spread bacteria, scales ranging from within patient, hospitals communities people. Model development starts treated pharmacokinetic pharmacodynamic principles are melded framework that mirrors interaction between bacterial population growth, drug treatment immunological responses targeted at...
We propose a mathematical model of the transmission dynamics colonization by commensal bacteria within human community subject to varying levels antibiotic use designed control morbidity induced pathogenic strains normally organisms. Colonization is assumed not induce in majority cases, and be related arrival growth that give rise infections including clinical symptoms disease. In absence resistance, shows how pattern prescription can eliminate non–pathogenic from host if fraction people...
We extend and develop our previous work on the evolution of a network cosmic strings. The new treatment is based an analysis probability distribution end-to-end distance, or extension, randomly chosen segment left-moving string given length. description involves three distinct length scales: \ensuremath{\xi}, related to overall density, \ensuremath{\xi}\ifmmode\bar\else\textasciimacron\fi{}, persistance along string, \ensuremath{\zeta}, describing small-scale structure, which important...
Abstract Objectives There are no published reports for anti‐interleukin‐5 therapy in children <12 years with asthma. The primary objective of this study was to characterize the pharmacokinetics and pharmacodynamics mepolizumab following subcutaneous (SC) administration 6 11 years‐of‐age severe eosinophilic Hypothesis Mepolizumab SC asthma comparable adults. Study Design Multinational, nonrandomised, open‐label (NCT02377427). Patient Selection Children (blood eosinophil count ≥150 cells/µL...
Aims To compare the airway potency, systemic activity and therapeutic index of three inhaled corticosteroids that differ in glucocorticoid receptor binding affinity, physicochemical pharmacokinetic properties. Methods This escalating‐dose, placebo‐controlled, cross‐over study randomised adults with asthma to 1 or 2 treatment periods ≥25 days washout in‐between. Each period comprised five 7‐day dose escalations (μg/d): fluticasone furoate (FF; 25 → 100 200 400 800), propionate (FP; 50 500...
Convenient administration of coronavirus disease 2019 (COVID-19) treatment in community settings is desirable. Sotrovimab a pan-sarbecovirus dual-action monoclonal antibody formulated for intravenous (IV) or intramuscular (IM) early mild/moderate COVID-19.
A simple epidemiological framework for the analysis of transmission dynamics hospital outbreaks epidemic methicillin-resistant Staphylococcus aureus (EMRSA) and vancomycin-resistant enterococci (VRE) in hospitals England Wales is presented. Epidemic strains EMRSA-15 EMRSA-16 are becoming endemic United Kingdom, theory predicts that will reach respective levels 158 (95% confidence interval [CI], 143-173) 116 CI, 109-123) affected with stochastic fluctuations up to 30 each case. An VRE still...
OBJECTIVE: To determine the effects of distinct ofatumumab dosing regimens compared to placebo on cumulative number new brain lesions assessed every 4 weeks for 12 weeks. BACKGROUND: Benefits anti-CD20 monoclonal antibody infusions have been demonstrated in RRMS. We investigated safety and efficacy four subcutaneous RRMS patients. DESIGN/METHODS: 232 subjects were randomized one 5 treatment groups: placebo, 3mg q12w, 30mg 60mg or q4w. Half each groups received a single initial dose at Week...
The evolution of a cosmic-string network is examined in terms two length scales: $\ensuremath{\xi}$, related to the long-string density, and persistence along left- or right-moving string, respectively. Previous work extended by allowing for dependence some parameters on these scales. changes have dramatic effects. As before an important role played parameter $q$ describing relative kinkiness loop as compared section string same length. We show that scaling solutions, which both...
MID3: Mission Impossible, or Model-Informed, Drug Discovery and Development? At the 2019 American Society for Clinical Pharmacology Therapeutics (ASCPT) annual meeting, point-counterpoint discussions were held on key challenges that limit, future directions enhance adoption of model-informed drug discovery development (MID3) across discovery, development, regulatory, utilization continuum. We envision opportunities discussed lessons learned from having contrasting perspectives issues lack...
Abstract Background COVID-19 disproportionately results in hospitalization and death older patients those with underlying comorbidities. Sotrovimab is a pan-sarbecovirus monoclonal antibody that binds highly conserved epitope of the SARS-CoV-2 receptor binding domain has an Fc modification increases half-life. retains activity against UK, S. Africa, Brazil, India, New York California variants vitro. Objectives To evaluate efficacy safety treatment sotrovimab high-risk, non-hospitalized...
Abstract Importance Older patients and those with underlying comorbidities infected SARS-CoV-2 may be at increased risk of hospitalization death from COVID-19. Sotrovimab is a neutralizing antibody designed for treatment high-risk to prevent COVID-19 progression. Objective To evaluate the efficacy safety sotrovimab in preventing progression mild moderate severe disease. Design Randomized, double-blind, multicenter, placebo-controlled, phase 3 study. Setting 57 centers 5 countries....
Abstract Dostarlimab (JEMPERLI) is an anti‐programmed cell death protein‐1 (PD‐1) monoclonal antibody (mAb) which approved by the US Food and Drug Administration for patients with recurrent/advanced mismatch repair‐deficient solid tumors, including endometrial cancer, following progression on prior treatment, approval based data from phase I GARNET trial. To support dostarlimab dose regimen recommendations, we estimated compared potency of relative to anti–PD‐1 mAb pembrolizumab using both...